New center’s aim: to ID biomarkers of neurodegenerative diseases (Links to an external site)

New center’s aim: to ID biomarkers of neurodegenerative diseases
A new center established at Washington University School of Medicine in St. Louis aims to accelerate research into biomarkers of neurodegenerative conditions such as Huntington’s and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and the so-called tauopathies, a group that includes Alzheimer’s disease along with rarer diseases such as frontotemporal dementia, corticobasal syndrome […]

Blood test for Alzheimer’s highly accurate in large, international study (Links to an external site)

Blood test for Alzheimer’s highly accurate in large, international study
“A blood test for Alzheimer’s provides a huge boost for Alzheimer’s research and diagnosis, drastically cutting the time and cost of identifying patients for clinical trials and spurring the development of new treatment options,” Bateman said. “As new drugs become available, a blood test could determine who might benefit from treatment, including those at very early stages of the disease.”

Consortium to investigate role of neurofilament light chain in neurodegenerative diseases (Links to an external site)

Consortium to investigate role of neurofilament light chain in neurodegenerative diseases
Clinical scientists at Washington University School of Medicine in St. Louis and University College London are collaborating with pharmaceutical companies AbbVie, Biogen, Bristol Myers Squibb and Roche to investigate the role of neurofilament light (NfL) chain in neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease.

UCL Queen Square Institute of Neurology joins consortium to investigate neurodegenerative diseases (Links to an external site)

UCL Queen Square Institute of Neurology joins consortium to investigate neurodegenerative diseases
This collaborative effort between UCL, Washington University, and pharmaceutical companies such as AbbVie, Biogen, Bristol Myers Squibb and Roche aims to better understand the structure and role of NfL across different neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease and Alzheimer’s disease.